Compare BHE & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | TWST |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1996 | 2018 |
| Metric | BHE | TWST |
|---|---|---|
| Price | $85.76 | $69.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $55.00 | $46.88 |
| AVG Volume (30 Days) | 331.1K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,659,108,000.00 | $376,572,000.00 |
| Revenue This Year | $7.03 | $18.91 |
| Revenue Next Year | $6.57 | $15.07 |
| P/E Ratio | $239.25 | ★ N/A |
| Revenue Growth | 0.11 | ★ 20.32 |
| 52 Week Low | $34.44 | $23.30 |
| 52 Week High | $89.40 | $80.50 |
| Indicator | BHE | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 61.29 |
| Support Level | $79.49 | $41.85 |
| Resistance Level | $88.27 | N/A |
| Average True Range (ATR) | 3.32 | 5.18 |
| MACD | -0.70 | 0.66 |
| Stochastic Oscillator | 64.58 | 63.98 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.